The α,β-heterodimeric hypoxia-inducible transcription factors (HIFs) are of central physiological importance in the response to chronic limited oxygen availability in animals.[@cit1]--[@cit5] HIF target genes include those encoding for multiple proteins of bio-medicinal importance, including erythropoietin (EPO), vascular endothelial growth factor (VEGF), and proteins involved in epigenetic regulation. Prolyl hydroxylation of HIF-α subunits signals for their degradation *via* the ubiquitin--proteasome system. Inhibition of the human HIF-α prolyl hydroxylases (PHD1-3) has the potential to mimic elements of the physiological hypoxic response. PHD inhibitors are in phase 3 clinical trials for the treatment of anaemia in chronic kidney disease, *via* upregulation of EPO ([Fig. 1](#fig1){ref-type="fig"}).[@cit1]--[@cit7] All of the PHD inhibitors currently in the clinical trials bind to the active site Fe([ii]{.smallcaps}) of the PHDs and compete with the 2-oxoglutarate (2OG) co-substrate.[@cit7],[@cit8] The extent to which the inhibitors compete with HIF-α, and maybe other PHD substrates varies.[@cit7],[@cit9],[@cit10] All of these PHD inhibitors have the potential to inhibit other human 2OG oxygenases, including other prolyl hydroxylases (*e.g.* procollagen and ribosomal prolyl hydroxylases).[@cit7] Many of the reported PHD inhibitors are structurally related to 2OG, and are relatively flat heteroaromatic compounds ([Fig. 1](#fig1){ref-type="fig"}).[@cit9]--[@cit11] Thus, there is a desire to generate new types of PHD inhibitors, with improved potency and selectivity. In this regard, the PHD inhibitors reported by Vachal *et al.*, are of interest because of their chiral spirocyclic nature ([Fig. 2, panel A](#fig2){ref-type="fig"}).[@cit12],[@cit13]

![The HIF prolyl hydroxylases are therapeutic targets. A. Prolyl-4-hydroxylation of prolyl residue in hypoxia inducible factor α (HIF-α) subunits, signals for degradation *via* the ubiquitin proteasome system. 2OG, 2-oxoglutarate; PHD1-3, human prolyl hydroxylase enzymes 1--3; VHL-E3 ligase: the von Hippel Lindau protein (VHL) is the targeting component of a ubiquitin E3 ligase system. B. Examples of PHD inhibitors in clinical trials. Roxadustat (FG-4592, **1**), daprodustat (GSK1278863, **2**), vadadustat (**3**), and molidustat (BAY 85-3924, **4**).[@cit6],[@cit7] Structures of 2OG and *N*-oxalylglycine a broad-spectrum 2OG oxygenase inhibitor are shown.](c8md00548f-f1){#fig1}

![Comparison of views from crystal structures from PHD2~181--407~·Mn^II^ in complex with **11** (PDB ; [6QGV](6QGV)) (A), **17** (PDB ; [4JZR](4JZR))[@cit13] (B) and **3** (PDB ; [5OX6](5OX6)) (C).[@cit7] Analysis of the binding modes of **11** & **17** reveal that they occupy the 2OG binding pocket and chelate the active site metal (Mn substituting for Fe) in a bidentate manner. Note the extent to which the PHD inhibitors project into the substrate binding pocket varies. In the case of the spiro\[4.5\]decanone inhibitors (A and B) the biphenyl ring group projects into an aromatic pocket formed by the side chains of Trp-258, Trp-389 and Phe-391, which are involved in substrate binding. The inhibitors also interact with the catalytically important residue Arg-322.[@cit16],[@cit17]](c8md00548f-f2){#fig2}

The spirocyclic core of the spiro\[4.5\]decanone series has potential for expansion into both the substrate and 2OG binding pockets of the PHDs ([Fig. 2](#fig2){ref-type="fig"}), and is apparently amenable to development of PHD selective and, more generally, 2OG oxygenase inhibitors.[@cit7] Limited SAR has been reported for the spiro\[4.5\]decanones series by Vachal *et al.* and Deng *et al.*, and no details for the potential of the series for selective inhibition has been described.[@cit12],[@cit13] Here we report SAR and structural studies of spiro\[4.5\]decanone containing PHD inhibitors (**11--16**, **23--27**, **36--44**).

Prior analyses of truncated PHD2 in complex with a spiro\[4.5\]decanone inhibitor reveal a binding mode involving chelation of the active site metal (Mn([ii]{.smallcaps}) was substituted for Fe([ii]{.smallcaps}) to produce a complex stable for crystallization) *via* the tertiary amine of its piperidine ring and a pyridinyl nitrogen ([Fig. 2](#fig2){ref-type="fig"}).[@cit13] Chelation of the active site metal of 2OG oxygenases by a pyridine ring is well precedented, *e.g.* with pyridine carboxylate inhibitors.[@cit14] However, tertiary alkylamine chelation as observed for **17** is less well documented, a rare example being daminozide (HO~2~CCH~2~CH~2~CONHNMe~2~), which inhibits specific JmjC histone demethylases (KDMs) *via* chelation of its carbonyl oxygen and the tertiary amine group of its acyl hydrazide.[@cit15]

There are three human HIF-α isoforms, with HIF-1α and HIF-2α having *N*- (NODD) and *C*-terminal (CODD) oxygen dependent degradation domains, each with a single prolyl hydroxylation site.[@cit1]--[@cit3] Work with the HIF hydroxylases has revealed differences outside of the 2-OG CH~2~CH~2~CO~2~H binding pocket that can be exploited to develop potent inhibitors.[@cit16] We therefore began by investigating substitution of the piperidone ring of the spiro\[4.5\]decanone series.

1,3,8-Triazaspiro\[4.5\]decane-2,4-dione (**11**) was synthesised by the route of Vachal *et al.* ([Fig. 3](#fig3){ref-type="fig"}).[@cit12] Thus, piperidone (**6**) underwent Bucherer--Berg reaction to give **7**; consecutive Ullmann couplings gave **8** then **9**; formic acid mediated Boc deprotection gave **10**. Reductive amination gave the targeted compounds **11--16** ([Fig. 3](#fig3){ref-type="fig"}).

![Synthesis of 3-(\[1,1′-biphenyl\]-4-yl)-8-((aryl)-1-(pyrimidin-2-yl)-1,3,8-triazaspiro-\[4.5\]-decane-2,4-dione compounds (**11--16**) to investigate the role of the pyrimidine group in tPHD2 inhibition. Conditions: a) KCN, NH~4~CO~3~, EtOH : H~2~O (1 : 1), 60 °C; b) CuI, K~2~CO~3~, 4-iodobiphenyl,*N*,*N*-dimethyl-ethylenediamine, ascorbate, DMF : CH~3~CN (1 : 1), reflux; c) 2-iodopyrimidine, CuI, TMHD, Cs~2~CO~3~, DMF : CH~3~CN (1 : 1), reflux; d) HCOOH, rt, 3 h; e) RCHO, NaBH(OAc)~3~, HCOOH. R~1~ = biphenyl.](c8md00548f-f3){#fig3}

**11--16** were then assayed using mass spectrometry (MS) for inhibition of the catalytic domain of truncated PHD2 (tPHD2, residues 181--426) and (in selected cases) PHD3, employing either human HIF-1α CODD or NODD peptide sequences ([Table 1](#tab1){ref-type="table"}). Details of the cellular activities of **11--16** and related compounds will be published elsewhere.

###### SAR of spiro\[4.5\]decanone containing inhibitors. Inhibitors were screened against tPHD2 with HIF-1α CODD and NODD substrates and PHD3 HIF1-α CODD substrate using a RapidFire mass spectrometer. Standard error of the mean (*n* = 3)
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  **10**                          H\--                              ![](c8md00548f-u2.jpg){#ugr2}     \>25            \>25
  **11**                          ![](c8md00548f-u3.jpg){#ugr3}     ![](c8md00548f-u4.jpg){#ugr4}     0.253 ± 0.047   0.127 ± 0.056
  **12**                          ![](c8md00548f-u5.jpg){#ugr5}     ![](c8md00548f-u6.jpg){#ugr6}     \>25            \>25
  **13**                          ![](c8md00548f-u7.jpg){#ugr7}     ![](c8md00548f-u8.jpg){#ugr8}     \>25            \>25
  **14**                          ![](c8md00548f-u9.jpg){#ugr9}     ![](c8md00548f-u10.jpg){#ugr10}   0.143 ± 0.097   0.049 ± 0.005
  **15**                          ![](c8md00548f-u11.jpg){#ugr11}   ![](c8md00548f-u12.jpg){#ugr12}   0.215 ± 0.019   0.070 ± 0.021
  **16**                          ![](c8md00548f-u13.jpg){#ugr13}   ![](c8md00548f-u14.jpg){#ugr14}   1.21 ± 0.226    0.905 ± 0.417
  **23**                          ![](c8md00548f-u15.jpg){#ugr15}   H\--                              0.741 ± 0.340   0.427 ± 0.122
  **24**                          ![](c8md00548f-u16.jpg){#ugr16}   H\--                              0.151 ± 0.035   0.063 ± 0.016
  **26**                          ![](c8md00548f-u17.jpg){#ugr17}   ![](c8md00548f-u18.jpg){#ugr18}   0.289 ± 0.011   0.055 ± 0.015
  **27**                          ![](c8md00548f-u19.jpg){#ugr19}   ![](c8md00548f-u20.jpg){#ugr20}   0.380 ± 0.064   0.094 ± 0.032

The inhibition results with **11--16** support the potential of the series for potent PHD inhibition and reveal potential for optimization. They reveal the importance of a chelating group at the 2-position of the pyridine ring or equivalent (the thiophene (**12**) and phenol (**13**) derivatives were inactive), and potential for variation in the metal chelating rings. Thus, the *N*-methyl imidazole (**14**) and imidazole (**15**) derivatives maintained potent inhibition comparable to (or better for the *N*-methyl imidazole (**14**)) the parent 3-methyl pyridine (**11**).[@cit12]

To inform the SAR work, crystal structures of tPHD2 in complex with our 1,3,8-triazaspiro\[4.5\]decane-2,4-dione compound series were pursued. We obtained a structure of tPHD2 in complex with **11** and Mn^II^ (substituting for Fe^II^) ([Fig. 2](#fig2){ref-type="fig"}, S1, S2 and S4 and Table S3[†](#fn1){ref-type="fn"}). The new structure reveals that **11** makes similar interactions with PHD2 to those observed for **17**.[@cit13] The 3-methyl pyridine ring of **11** penetrates into the 2OG binding pocket.[@cit7],[@cit8] The active site metal is chelated by the tertiary amine of the piperidine ring and 3-methyl pyridinyl nitrogen of **11**. The biphenyl substituent of **11** is positioned in an aromatic pocket formed by the Trp-258, Trp-389 and Phe-391 side-chains, with which it makes hydrophobic/π-stacking interactions. The terminal phenyl ring of the biphenyl substituent of **11** is positioned to form a cation π-interaction with the catalytically important residue Arg-322.[@cit17],[@cit18] Arg-322 is also positioned to hydrogen bond to the imidazolidine-2,4-dione ring of **11** ([Fig. 2, panel A](#fig2){ref-type="fig"}). The pyrimidine ring of **11**, which is not present in **17**, is positioned to form a π-stacking interaction with the phenol ring of Tyr-310. The presence of the pyrimidine ring of **11** also apparently changes the conformations of catalytically important residues, including Tyr-303 and Tyr-310, compared to their conformations as observed in the structures of tPHD2 in complex with the close 2-OG analogue *N*-oxalylglycine (NOG) (Fig. S1, panel F[†](#fn1){ref-type="fn"}) or 2,8-diazaspiro\[4.5\]decan-1-one **17** ([Fig. 2, panel B](#fig2){ref-type="fig"}).[@cit13],[@cit17],[@cit18]

From the initial work on the spiro\[4.5\]decanone series, it was unclear whether the pyrimidine ring of **11** is required for PHD2 inhibition. A series of analogues of **11** (Fig. S3, panel A[†](#fn1){ref-type="fn"}), wherein the pyrimidine ring was removed or modified, based on interactions observed in the PHD2:**11** structure, (Fig. S3, panel A[†](#fn1){ref-type="fn"}), were therefore prepared.

**23--26**, were synthesised using the same route as before (Scheme S1[†](#fn1){ref-type="fn"}). The inhibition results with these derivatives reveal the pyrimidine ring has a minor role in enabling potent tPHD2 inhibition, *i.e.* the non-pyrimidine containing analogues **23** are only somewhat weaker compared to **11** (IC~50~**11**, 0.253 μM; **23**, 0.741 μM). The substituted pyridyl analogues, such as **27**, were as active as **11** (IC~50~**11**, 0.253 μM; **26**, 0.289 μM; **27**, 0.333 μM). Previous work has shown that pyridine carboxylates can bind in the 2-OG pocket, but this seems unlikely to be the case for the pyridine carboxylate ring of **27**, as shown by our crystallographic analysis of **11** ([Fig. 2 panel A](#fig2){ref-type="fig"}, S1 and S2[†](#fn1){ref-type="fn"}).[@cit14]

We then investigated the importance of the imidazol-idine-2,4-dione ring of **11** using compounds **36--44** (Fig. S3, panel B[†](#fn1){ref-type="fn"}). It was envisaged that replacement of the imidazolidine-2,4-dione ring with an amide group might fulfill the requirement for a linker of appropriate length between the elements binding in the 2-OG binding and aromatic ring binding pockets ([Fig. 2, panel A](#fig2){ref-type="fig"}). Substituents interacting with both the 2-OG binding and 'aromatic' pockets were varied in **36--44**. For the aromatic pocket binding groups, either 4-biphenyl or the 4-phenylbenzyl groups were used. For the heteroaromatic metal binding substituent, 3-methyl pyridine and phenol substituents were chosen as they had previously manifested different levels of inhibition ([Table 1](#tab1){ref-type="table"}).

The 3-hydroxypyridine derivatives **38**, **41** and **44** were produced because analysis of the PHD2 structure in complex with **11** ([Fig. 2, panel A](#fig2){ref-type="fig"}) suggested that replacing the methyl group of **11** with a hydroxyl group may form additional interactions with PHD2, *via* hydrogen bonding to either Tyr-310 or Tyr-303 ([Fig. 2, panel A](#fig2){ref-type="fig"}). To prepare **36--44**, the requisite carboxylic acids were coupled with the requisite amines to give **29**, **30**, **32**, which underwent Pd catalysed deprotection to provide the amines **33--35**. Application of the reductive amination conditions developed for the 1,3,8-triazaspiro\[4.5\]-decane-2,4-dione series, gave the targeted compounds **36--44** (Scheme S2[†](#fn1){ref-type="fn"}). The imidazole2,4-dione analogues **36--44** were inactive, implying an important role for the imidazolidine-2,4-dione core and a relatively rigid linker between elements binding in the aromatic and 2OG binding pockets (Table S1[†](#fn1){ref-type="fn"}).

We carried out initial studies on the selectivity of the spiro\[4.5\]decanone series. The assay results with tPHD2 and either HIF-1α NODD or CODD as substrates showed similar results in terms of rank order ([Table 1](#tab1){ref-type="table"}). However, the IC~50~ values for NODD were in general lower than for CODD, perhaps reflecting its lower efficiency as a tPHD2 substrate.[@cit2]--[@cit4] Several of the compounds were tested as PHD3 inhibitors and were observed to inhibit PHD3 catalysed either HIF-1α CODD hydroxylation at similar levels observed for PHD2 inhibition (PHD3 IC~50~ values: **11**, 3.95 ± 0.75 μM; **23**, 1.05 ± 0.04 μM; **24**, 0.219 ± 0.025 μM). This observation suggests that the spiro\[4,5\]decanone core is not, at least intrinsically, PHD2 isoform selective. However, the differences in IC~50~ values for tPHD2 and PHD3 also suggest that modification of the spiro\[4,5\]decanone core might be exploited for development of PHD isoform selective inhibitors. However, care should also be taken when assessing the results with isolated HIF-α fragments and initial kinetic assays as employed here, which may not translate to a cellular context. Further evidence that spiro\[4.5\]decanones have potential as useful 2OG oxygenase inhibitors comes from selectivity studies on compounds **11--16**, **23--27** with isolated forms of two other human oxygenases, *i.e.* the HIF-α asparaginyl hydroxylase factor inhibiting HIF (FIH) and a JmjC *N*^ε^-methyl lysine histone demethylase (KDM4).[@cit7] For all the tested compounds either no (*i.e.* IC~50~ \>25 mM) or weak (**26** with FIH; **11**, **14** with KDM4A) inhibition was observed (Table S2[†](#fn1){ref-type="fn"}). The lack of activity *versus* FIH is important because this enzyme has non HIF-α substrates.[@cit19] Thus, spiro\[4.5\]decanone derivatives have potential use in dissecting the roles of individual HIF-α hydroxylases.

Together with previous work, our overall results reveal spiro\[4.5\]decanones as having considerable potential for inhibition of the PHDs.[@cit12] Initial selectivity studies have demonstrated the potential for selective 2-OG oxygenase inhibition by spiro\[4.5\]decanones series (Table S2[†](#fn1){ref-type="fn"}). More generally, the results reveal the potential for combining active site metal chelation with 3-dimensional elements to enable selectivity in the inhibition of 2-OG oxygenases.
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